Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21990701 | 0.89 | PIK3CD (0.34) | CYP17A1CYP3A4PIM1PIM2PIK3CD | |
| SCHEMBL23988004 | 0.86 | MAP4K1 (0.31) | CYP17A1CYP3A4 | |
| SCHEMBL21990556 | 0.80 | MAP4K1 (0.32) | CYP17A1CYP3A4PIM1PIM2PIK3CD | |
| SCHEMBL21990455 | 0.80 | MAP4K1 (0.36) | CYP17A1CYP3A4PIM1PIM2PIK3CD | |
| SCHEMBL21964196 | 0.77 | MAP4K1 (0.33) | — | |
| SCHEMBL23987764 | 0.77 | USP8 (0.32) | PIM1PIM2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL25100324 | 0.77 | MAP4K1 (0.42) | CYP17A1CYP3A4PIM1PIM2PIK3CD | |
| SCHEMBL21990542 | 0.75 | NPSR1 (0.35) | PIM1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL21990672 | 0.75 | MAP4K1 (0.46) | — | |
| SCHEMBL21964197 | 0.75 | MAP4K1 (0.35) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | PFIZER INC. (US) | 2023-06-27 | — | — | US | disclosed |
| CN-115698004-A | Azalactam compounds as HPK1 inhibitors | 辉瑞公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | PFIZER INC. (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2021220185-A1 | AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | PFIZER INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401424-A1 | Azalactam Compounds as HPK1 Inhibitors | CDKN1A, HIPK1, CMPK1 | CYP17A1 2762/4885CYP3A4 3058/4885PIM1 1945/4885 |
| US-11684616-B2 | Azalactam compounds as HPK1 inhibitors | CDKN1A, HIPK1, CMPK1 | CYP17A1 2762/4885CYP3A4 3058/4885PIM1 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.